Last reviewed · How we verify
ARN-509
ARN-509 is an androgen receptor inhibitor.
ARN-509 is an androgen receptor inhibitor. Used for Metastatic castration-resistant prostate cancer.
At a glance
| Generic name | ARN-509 |
|---|---|
| Also known as | apalutamide, JNJ-56021927 |
| Sponsor | Aragon Pharmaceuticals, Inc. |
| Drug class | Androgen receptor inhibitor |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ARN-509 works by binding to the androgen receptor, preventing it from interacting with androgens such as testosterone and dihydrotestosterone, which are involved in the growth and spread of prostate cancer cells.
Approved indications
- Metastatic castration-resistant prostate cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Muscle spasm
- Headache
Key clinical trials
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (PHASE3)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (PHASE2)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (PHASE3)
- Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (PHASE2)
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARN-509 CI brief — competitive landscape report
- ARN-509 updates RSS · CI watch RSS
- Aragon Pharmaceuticals, Inc. portfolio CI